A Bioartificial Pancreas: What the VANGUARD Project Aims to Achieve for Type 1 Diabetes

Type 1 diabetes affects more than 2.2 million people in Europe. Unlike Type 2 diabetes, Type 1 occurs when the body's immune system attacks the cells in the pancreas that produce insulin. There is currently no cure.

People with Type 1 diabetes manage their condition through continuous blood sugar monitoring and insulin injections. More advanced treatment options exist, but they come with significant limitations and risks. For instance, pancreatic islet transplantation—transplanting insulin-producing cells from a donor pancreas—can help restore some blood sugar control. However, this approach faces two major obstacles: there simply aren't enough donor organs available, and patients must take immunosuppressive medications for life to prevent their immune system from rejecting the transplant.

Over five years, the EU-funded VANGUARD project brought together six partner institutions to develop a novel solution: a bioartificial pancreas. This is an implantable medical device that combines insulin-producing cell clusters with a protective biomaterial.

The core idea is straightforward: the device does the work a damaged pancreas cannot do—it restores the body's natural ability to regulate blood sugar on its own. According to Ekaterine Berishvili, the project coordinator and a medical doctor at the University of Geneva School of Medicine, the goal was to engineer "a construct containing insulin-producing cell clusters embedded in a protective biomaterial that can restore normal blood sugar without having to rely on donor organs or suppressing the patient's immune system."

The bioartificial pancreas addresses two critical problems with current transplant options. First, it does not depend on scarce human donor organs. Second, it is designed to work without requiring patients to take immunosuppressive drugs, which can cause serious side effects and leave people vulnerable to infection.

Another important feature is that the device is retrievable. This means it can be implanted and, if necessary, removed—a safety characteristic that distinguishes it from permanent implants and may make it more acceptable to patients and clinicians as research advances.

The VANGUARD project has completed its five-year development phase. The existence of this prototype represents meaningful progress in diabetes research, but it is important to understand that this device is not yet available as a treatment. Significant work remains before any bioartificial pancreas could be tested in patients or approved for clinical use.

As research continues, the bioartificial pancreas represents one promising direction among many being explored to improve—and potentially transform—how Type 1 diabetes is managed in the future.

Origin: CORDIS | European Commission (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.